Xofluza Granule, For Suspension
Product Images NDC 50242-599

16 FDA label images from Genentech, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Xofluza (NDC 50242-599). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xofluza 01)

Chemical Structure (Xofluza 01)
Chemical structure of Baloxavir Marboxil, the active ingredient in Xofluza. The diagram shows the molecular arrangement of atoms including fluorine, sulfur, oxygen, nitrogen, and carbon components characteristic to this antiviral compound.*
FDA Label Image

Image (Xofluza 02)

FDA Label Image

Figure A (Xofluza 03)

Figure A (Xofluza 03)
Xofluza (baloxavir marboxil) oral suspension label for the 40 mg/20 mL (2 mg/mL) strength. The label indicates it is a granular oral suspension with instructions on dosing as a single one-time dose, measuring device use, and storage. The product is labeled by Genentech, Inc.*
FDA Label Image

Figure B (Xofluza 04)

Figure B (Xofluza 04)
Label for Xofluza (baloxavir marboxil) 40 mg tablet. The label specifies a total dose of 40 mg per tablet and includes instructions stating to take the tablet as a single, one-time dose. The label also displays the NDC number 50242-860-01 and the manufacturer labeler Genentech.*
FDA Label Image

Figure C (Xofluza 05)

Figure C (Xofluza 05)
Label for Xofluza (baloxavir marboxil) 80 mg tablet. The label indicates the total dose is one 80 mg tablet and provides usual dosage instructions for a single, one-time dose. The label also features the Genentech logo and NDC 50242-877-01.*
FDA Label Image

Figure D (Xofluza 06)

Figure D (Xofluza 06)
An instructional illustration showing a person administering oral suspension to a child using a cup. The child's face is in profile, and a hand holds the cup to the child's mouth, demonstrating how to give the medication orally.*
FDA Label Image

Figure E (Xofluza 07)

Figure E (Xofluza 07)
An instructional illustration showing a clear glass partially filled with liquid next to a glass with a small amount of powder inside. Arrows indicate swirling or stirring the powder in the liquid to mix a suspension, likely for oral administration.*
FDA Label Image

Figure F (Xofluza 08)

Figure F (Xofluza 08)
Illustration showing a hand holding a single-use packet of medication under running water from a faucet with a cup nearby, likely depicting how to open or prepare the granule for suspension dosage form.*
FDA Label Image

Figure G (Xofluza 09)

Figure G (Xofluza 09)
An instructional illustration showing a hand holding a syringe, withdrawing liquid from a small cup. The image likely demonstrates preparation or dosing steps for oral administration of a medication suspension.*
FDA Label Image

Figure H (Xofluza 10)

Figure H (Xofluza 10)
Instructional illustration showing two steps for preparing an oral suspension with Xofluza granules. The first step depicts a hand holding a syringe to withdraw liquid from a container. The second step shows the liquid being administered orally using the syringe. The illustrations are black and white line drawings without text.*
FDA Label Image

Figure I (Xofluza 11)

Figure I (Xofluza 11)
An instructional illustration showing two cups and a spoon. The image depicts transferring liquid from one cup to another and stirring the contents in the second cup, likely demonstrating how to prepare or mix a suspension.*
FDA Label Image

Principal Display Panel (40 mg/20 mL Bottle Carton)

Principal Display Panel (40 mg/20 mL Bottle Carton)
Label for Xofluza (baloxavir marboxil) oral suspension, 40 mg/20 mL (2 mg/mL) strength. The label states the suspension is for oral use with each mL containing 2 mg of baloxavir marboxil. It advises taking the prescribed dose as a single one-time dose and discarding any unused portion, using an appropriate measuring device. The total usable volume after constitution is 20 mL. The product is manufactured by Genentech, Inc.*
FDA Label Image

Principal Display Panel (40 mg Tablet Blister Pack Carton)

Principal Display Panel (40 mg Tablet Blister Pack Carton)
This panel provides dosage information for Xofluza (baloxavir marboxil) 40 mg tablet. It specifies the total dose as one 40 mg tablet and notes the usual dosage is a single, one-time dose. The labeler is Genentech, Inc., with NDC 50242-860-01.*
FDA Label Image

Principal Display Panel (80 mg Tablet Blister Pack Carton)

Principal Display Panel (80 mg Tablet Blister Pack Carton)
Xofluza (baloxavir marboxil) 80 mg tablet packaging label showing the total dose as one 80 mg tablet. The label includes usage instructions mentioning a single, one-time dose per package. The labeler is Genentech, Inc. and the NDC is 50242-877-01.*
FDA Label Image

Principal Display Panel (30 mg Packet Carton)

Principal Display Panel (30 mg Packet Carton)
Label for Xofluza 30 mg per packet granules for oral suspension. The label shows the product name, generic name (baloxavir marboxil), dosage strength, and instructions to refer to the carton for use. It is labeled for prescription use only and manufactured by Genentech, Inc.*
FDA Label Image

Principal Display Panel (40 mg Packet Carton)

Principal Display Panel (40 mg Packet Carton)
Label for Xofluza (baloxavir marboxil) oral suspension granules showing strength of 40 mg per packet. The label includes instructions to refer to the carton for use directions and is marked for Rx use only. Labeler is Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.